← Leaderboards
Elliot Chaikof
Beth Israel Deaconess Medical Center
$40,570,541
Attributed
$52,961,341
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,961,341 · 20
By mechanism
R01$37,581,953 · 15
U01$6,929,027 · 2
K12$4,804,055 · 1
UG3$2,260,670 · 1
UH3$1,385,636 · 1
Top collaborators
- Richard D Cummings11 shared
- Robert C Flaumenhaft5 shared
- Robert Sackstein5 shared
- Jeffrey Zwicker5 shared
- Mark W Grinstaff4 shared
- Barbara B Kahn4 shared
- Torsten Bjoern Meissner4 shared
- Lijun Sun4 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Bruce Furie$39,376,853
- Frank W Logerfo$21,342,043
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroDesignResponseBasePathway InteractionsCellsProteinsPropertySurfaceGenerationsEffectivenessMediatingMimeticsLigandsPeptidesVariantInflammatory ResponseInvestigationBiologicalInnovationThrombusStructureBlood
Grant awards (102)
Rechargeable Anti-thrombogenic Films for Blood Contacting Applications$724,920
R01 · FY2025 · HL · contact PI
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,947
R01 · FY2025 · DK · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$639,742
R01 · FY2025 · HL
Immunoevasive Engineered Living Blood Vessels$604,246
R01 · FY2025 · EB · contact PI
Rechargeable Anti-thrombogenic Films for Blood Contacting Applications$761,370
R01 · FY2024 · HL · contact PI
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$677,710
R01 · FY2024 · DK · contact PI
Immunoevasive Engineered Living Blood Vessels$592,162
R01 · FY2024 · EB · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$551,239
R01 · FY2024 · HL
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,947
R01 · FY2023 · DK · contact PI
Immunoevasive Engineered Living Blood Vessels$604,246
R01 · FY2023 · EB · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$562,489
R01 · FY2023 · HL
Delivery Technologies for In Vivo Genome Editing$1,385,636
UH3 · FY2022 · AI · contact PI
Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education$958,467
K12 · FY2022 · HL
Biomarkers and mechanisms in cancer associated thrombosis$829,929
U01 · FY2022 · HL
Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD$705,835
R01 · FY2022 · DK · contact PI
Immunoevasive Engineered Living Blood Vessels$611,830
R01 · FY2022 · EB · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$553,824
R01 · FY2022 · HL
Clot-Targeted Antithrombotics for Venous Thromboprophylaxis$465,803
R01 · FY2022 · HL · contact PI
Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education$958,467
K12 · FY2021 · HL
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2021 · HL
Delivery Technologies for In Vivo Genome Editing$711,044
UG3 · FY2021 · AI · contact PI
Clot-Targeted Antithrombotics for Venous Thromboprophylaxis$488,240
R01 · FY2021 · HL · contact PI
Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education$958,467
K12 · FY2020 · HL
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2020 · HL
Delivery Technologies for In Vivo Genome Editing$752,780
UG3 · FY2020 · AI · contact PI
Clot-Targeted Antithrombotics for Venous Thromboprophylaxis$404,000
R01 · FY2020 · HL · contact PI
Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education$958,467
K12 · FY2019 · HL
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2019 · HL
Delivery Technologies for In Vivo Genome Editing$796,846
UG3 · FY2019 · AI · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic Syndrome$586,112
R01 · FY2019 · DK · contact PI
Clot-Targeted Antithrombotics for Venous Thromboprophylaxis$422,750
R01 · FY2019 · HL · contact PI
Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education$970,187
K12 · FY2018 · HL
Biomarkers and mechanisms in cancer associated thrombosis$893,486
U01 · FY2018 · HL
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$680,123
U01 · FY2018 · GM · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic Syndrome$586,112
R01 · FY2018 · DK · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Venous Thromboembolism$435,000
R01 · FY2018 · HL · contact PI
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$132,346
U01 · FY2018 · GM · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic Syndrome$671,542
R01 · FY2017 · DK · contact PI
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$567,980
U01 · FY2017 · GM · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Venous Thromboembolism$435,000
R01 · FY2017 · HL · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic Syndrome$638,976
R01 · FY2016 · DK · contact PI
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$567,980
U01 · FY2016 · GM · contact PI
In Situ Regeneration of Bioactive Surfaces: Rechargeable Anti-thrombogenic Films$421,743
R01 · FY2016 · HL · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Venous Thromboembolism$417,800
R01 · FY2016 · HL · contact PI
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$25,000
U01 · FY2016 · GM · contact PI
Facile Synthesis of Glycosulfopeptides and Related Bioconjugates$607,975
U01 · FY2015 · GM · contact PI
A PSGL-1 Glycopeptide Mimetic for Treatment of Venous Thromboembolism$454,800
R01 · FY2015 · HL · contact PI
In Situ Regeneration of Bioactive Surfaces: Rechargeable Anti-thrombogenic Films$415,416
R01 · FY2015 · HL · contact PI
In Situ Regeneration of Bioactive Surfaces: Rechargeable Anti-thrombogenic Films$413,308
R01 · FY2014 · HL · contact PI
Site-Specific Therapies To Prevent Intimal Hyperplasia$390,040
R01 · FY2014 · HL · contact PI
In Situ Regeneration of Bioactive Surfaces: Rechargeable Anti-thrombogenic Films$443,827
R01 · FY2013 · HL · contact PI
Site-specific therapies to prevent intimal hyperplasia$378,896
R01 · FY2013 · HL · contact PI
Molecularly Engineered Blockade of Islet Induced Inflammatory Responses$340,244
R01 · FY2013 · DK · contact PI
Site-specific therapies to prevent intimal hyperplasia$398,000
R01 · FY2012 · HL · contact PI
Syndecan-1 in Aortic Aneurysm Formation$387,585
R01 · FY2012 · HL · contact PI
Molecularly Engineered Blockade of Islet Induced Inflammatory Responses$352,009
R01 · FY2012 · DK · contact PI
Site-specific therapies to prevent intimal hyperplasia$416,500
R01 · FY2011 · HL · contact PI
Syndecan-1 in Aortic Aneurysm Formation$391,500
R01 · FY2011 · HL · contact PI
Molecularly Engineered Blockade of Islet Induced Inflammatory Responses$351,448
R01 · FY2011 · DK · contact PI
A Bioinspired Small Diameter Vascular Conduit$837,584
R01 · FY2010 · HL · contact PI
Anti-Thrombogenic Membrane-Mimetic Assemblies$470,675
R01 · FY2010 · HL · contact PI
Syndecan-1 in Aortic Aneurysm Formation$344,001
R01 · FY2010 · HL · contact PI
Molecularly Engineered Blockade of Islet Induced Inflammatory Responses$240,726
R01 · FY2010 · DK · contact PI
Molecularly Engineered Blockade of Islet Induced Inflammatory Responses$187,281
R01 · FY2010 · DK · contact PI
A Bioinspired Small Diameter Vascular Conduit$777,253
R01 · FY2009 · HL · contact PI
Anti-Thrombogenic Membrane-Mimetic Assemblies$414,287
R01 · FY2009 · HL · contact PI
Syndecan-1 in Aortic Aneurysm Formation$344,074
R01 · FY2009 · HL · contact PI
A Bioinspired Small Diameter Vascular Conduit$975,445
R01 · FY2008 · HL · contact PI
Anti-Thrombogenic Membrane-Mimetic Assemblies$414,264
R01 · FY2008 · HL · contact PI
Syndecan-1 in Aortic Aneurysm Formation$357,480
R01 · FY2008 · HL · contact PI
Barrier for Intraportal Islet Transplantation$322,528
R01 · FY2008 · DK · contact PI
A Bioinspired Small Diameter Vascular Conduit$639,327
R01 · FY2007 · HL · contact PI
Anti-Thrombogenic Membrane-Mimetic Assemblies$414,257
R01 · FY2007 · HL · contact PI
Barrier for Intraportal Islet Transplantation$329,110
R01 · FY2007 · DK · contact PI
Autogeneration of an Artery: A Biomimetric Strategy$326,412
R01 · FY2007 · HL · contact PI
A Bioinspired Small Diameter Vascular Conduit$557,353
R01 · FY2006 · HL · contact PI
Barrier for Intraportal Islet Transplantation$338,939
R01 · FY2006 · DK · contact PI
Autogeneration of an Artery: A Biomimetric Strategy$336,161
R01 · FY2006 · HL · contact PI
Anti-Thrombogenic Membrane-Mimetic Assemblies$330,357
R01 · FY2006 · HL · contact PI
Protein Fibers as Design Elements for Arterial Conduit$519,430
R01 · FY2005 · HL
Barrier for Intraportal Islet Transplantation$347,890
R01 · FY2005 · DK
Autogeneration of an Artery: A Biomimetric Strategy$344,250
R01 · FY2005 · HL
Syndecan Shedding in Vascular Lesion Formation$304,000
R01 · FY2005 · HL
Protein Fibers as Design Elements for Arterial Conduit$528,537
R01 · FY2004 · HL
ANTITHROMBOGENIC MEMBRANE-MIMETIC ASSEMBLIES$380,000
R01 · FY2004 · HL
Barrier for Intraportal Islet Transplantation$359,550
R01 · FY2004 · DK
Autogeneration of an Artery: A Biomimetric Strategy$344,250
R01 · FY2004 · HL
Syndecan Shedding in Vascular Lesion Formation$304,000
R01 · FY2004 · HL
Protein Fibers as Design Elements for Arterial Conduit$509,975
R01 · FY2003 · HL
ANTITHROMBOGENIC MEMBRANE-MIMETIC ASSEMBLIES$359,720
R01 · FY2003 · HL
Syndecan Shedding in Vascular Lesion Formation$304,000
R01 · FY2003 · HL
Protein Fibers as Design Elements for Arterial Conduit$609,120
R01 · FY2002 · HL
A BIOMIMETIC BARRIER FOR ISLET IMMUNOISOLATION$401,519
R01 · FY2002 · RR
ANTITHROMBOGENIC MEMBRANE-MIMETIC ASSEMBLIES$359,720
R01 · FY2002 · HL
AUTOGENERATION OF AN ARTERY--A BIOMIMETIC STRATEGY$309,000
R01 · FY2002 · HL
A BIOMIMETIC BARRIER FOR ISLET IMMUNOISOLATION$390,507
R01 · FY2001 · RR
ANTITHROMBOGENIC MEMBRANE-MIMETIC ASSEMBLIES$366,970
R01 · FY2001 · HL
AUTOGENERATION OF AN ARTERY--A BIOMIMETIC STRATEGY$309,000
R01 · FY2001 · HL
SYNDECAN-4 IN VASCULAR SMOOTH MUSCLE CELL MIGRATION$241,337
R01 · FY2001 · HL
A BIOMIMETIC BARRIER FOR ISLET IMMUNOISOLATION$379,817
R01 · FY2000 · RR
AUTOGENERATION OF AN ARTERY--A BIOMIMETIC STRATEGY$309,000
R01 · FY2000 · HL
SYNDECAN-4 IN VASCULAR SMOOTH MUSCLE CELL MIGRATION$234,689
R01 · FY2000 · HL